Last reviewed 2026-05-13 · How we verify

Vaccination with M.vaccae

British Thoracic Society · FDA-approved active Biologic Quality 1/100

Vaccination with M.vaccae is a Biologic drug developed by British Thoracic Society. It is currently FDA-approved.

At a glance

Generic name	Vaccination with M.vaccae
Sponsor	British Thoracic Society
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vaccination with M.vaccae CI brief — competitive landscape report
Vaccination with M.vaccae updates RSS · CI watch RSS
British Thoracic Society portfolio CI

Frequently asked questions about Vaccination with M.vaccae

What is Vaccination with M.vaccae?

Vaccination with M.vaccae is a Biologic drug developed by British Thoracic Society.

Who makes Vaccination with M.vaccae?

Vaccination with M.vaccae is developed and marketed by British Thoracic Society (see full British Thoracic Society pipeline at /company/british-thoracic-society).

What development phase is Vaccination with M.vaccae in?

Vaccination with M.vaccae is FDA-approved (marketed).

Manufacturer: British Thoracic Society — full pipeline